In response to price gouging and supply shortage concerns, Franklin Scott Conway LLP coordinated the delivery of the generous donation by Amneal Pharmaceuticals of over 6.5 million doses of Hydroxychloroquine to states representing over 40% of the U.S. population in a remarkable pro bono initiative that required the full-time effort of several of the firm’s professionals. Numerous state officials assisting in the COVID-19 response praised Amneal and the firm for their efforts.
The firm volunteered for this operation because of its significant contacts with state and local governments, deep knowledge of the pharmaceutical distribution system, and founding purpose to collaboratively support the causes and people whose success can improve the lives, souls, and environments of others. In this instance, the firm collaboratively supported a great American company, Amneal Pharmaceuticals, the sole U.S. manufacturer of Hydroxychloroquine.
When Amneal’s Hydroxychloroquine supply ran low after donating 10,000 doses to West Virginia, FSC secured an additional donation of 40,000 doses for West Virginia from Mylan Inc. FSC thanks Mylan for its generous donation!
Hydroxychloroquine is currently used to treat childhood arthritis, Lupus, and rheumatoid arthritis. Some doctors have also prescribed Hydroxychloroquine as an off-label treatment for COVID-19, and it is also being used in several clinical trials to determine its effectiveness as a COVID-19 treatment.
Franklin Scott Conway’s pro bono effort enabled over 6.5 million doses of Hydroxychloroquine to be delivered for free to states who wanted to guard against supply chain interruption and price-gouging.